Literature DB >> 25183580

Classification of hypervascular liver lesions based on hepatic artery and portal vein blood supply coefficients calculated from triphasic CT scans.

F Edward Boas1, Aya Kamaya, Bao Do, Terry S Desser, Christopher F Beaulieu, Shreyas S Vasanawala, Gloria L Hwang, Daniel Y Sze.   

Abstract

Perfusion CT of the liver typically involves scanning the liver at least 20 times, resulting in a large radiation dose. We developed and validated a simplified model of tumor blood supply that can be applied to standard triphasic scans and evaluated whether this can be used to distinguish benign and malignant liver lesions. Triphasic CTs of 46 malignant and 32 benign liver lesions were analyzed. For each phase, regions of interest were drawn in the arterially enhancing portion of each lesion, as well as the background liver, aorta, and portal vein. Hepatic artery and portal vein blood supply coefficients for each lesion were then calculated by expressing the enhancement curve of the lesion as a linear combination of the enhancement curves of the aorta and portal vein. Hepatocellular carcinoma (HCC) and hypervascular metastases, on average, both had increased hepatic artery coefficients compared to the background liver. Compared to HCC, benign lesions, on average, had either a greater hepatic artery coefficient (hemangioma) or a greater portal vein coefficient (focal nodular hyperplasia or transient hepatic attenuation difference). Hypervascularity with washout is a key diagnostic criterion for HCC, but it had a sensitivity of 72 % and specificity of 81 % for diagnosing malignancy in our diverse set of liver lesions. The sensitivity for malignancy was increased to 89 % by including enhancing lesions that were hypodense on all phases. The specificity for malignancy was increased to 97 % (p = 0.039) by also examining hepatic artery and portal vein blood supply coefficients, while maintaining a sensitivity of 76 %.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25183580      PMCID: PMC4359206          DOI: 10.1007/s10278-014-9725-9

Source DB:  PubMed          Journal:  J Digit Imaging        ISSN: 0897-1889            Impact factor:   4.056


  26 in total

Review 1.  Perfusion imaging of the liver: current challenges and future goals.

Authors:  Pari V Pandharipande; Glenn A Krinsky; Henry Rusinek; Vivian S Lee
Journal:  Radiology       Date:  2005-03       Impact factor: 11.105

2.  Value of the unenhanced phase for detection of hepatocellular carcinomas 3 cm or less when performing multiphase computed tomography in patients with cirrhosis.

Authors:  Deirdre J Doyle; Martin E O'Malley; Hyun-Jung Jang; Kartik Jhaveri
Journal:  J Comput Assist Tomogr       Date:  2007 Jan-Feb       Impact factor: 1.826

3.  Maximization of the sum of sensitivity and specificity as a diagnostic cutpoint criterion.

Authors:  Kim Kaivanto
Journal:  J Clin Epidemiol       Date:  2008-01-14       Impact factor: 6.437

Review 4.  Understanding transient hepatic attenuation differences.

Authors:  Terry S Desser
Journal:  Semin Ultrasound CT MR       Date:  2009-10       Impact factor: 1.875

5.  Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver.

Authors:  Asra S Khan; Hero K Hussain; Timothy D Johnson; William J Weadock; Shawn J Pelletier; Jorge A Marrero
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

6.  Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma.

Authors:  Luigi Bolondi; Stefano Gaiani; Natascia Celli; Rita Golfieri; Walter Francesco Grigioni; Simona Leoni; Anna Maria Venturi; Fabio Piscaglia
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

7.  Assessment of tumor vascularization with functional computed tomography perfusion imaging in patients with cirrhotic liver disease.

Authors:  Jin-Ping Li; De-Li Zhao; Hui-Jie Jiang; Ya-Hua Huang; Da-Qing Li; Yong Wan; Xin-Ding Liu; Jin-E Wang
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-02

8.  Quantitative CT color mapping of the arterial enhancement fraction of the liver to detect hepatocellular carcinoma.

Authors:  Kyung Won Kim; Jeong Min Lee; Ernst Klotz; Hee Sun Park; Dong Ho Lee; Ji Young Kim; Soo Jin Kim; Se Hyung Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2009-02       Impact factor: 11.105

9.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  12 in total

1.  Quantitative Measurements of Enhancement on Preprocedure Triphasic CT Can Predict Response of Colorectal Liver Metastases to Radioembolization.

Authors:  F Edward Boas; Lynn A Brody; Joseph P Erinjeri; Hooman Yarmohammadi; Waleed Shady; Sirish Kishore; Constantinos T Sofocleous
Journal:  AJR Am J Roentgenol       Date:  2016-06-01       Impact factor: 3.959

2.  Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial.

Authors:  F Edward Boas; Nancy E Kemeny; Constantinos T Sofocleous; Randy Yeh; Vanessa R Thompson; Meier Hsu; Chaya S Moskowitz; Etay Ziv; Hooman Yarmohammadi; Achiude Bendet; Stephen B Solomon
Journal:  Radiology       Date:  2021-08-31       Impact factor: 11.105

Review 3.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

4.  [Hepatocellular carcinomas and their mimics].

Authors:  H-P Fischer; D Goltz
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

5.  Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma?

Authors:  Alessandra Borgheresi; Adrian Gonzalez-Aguirre; Karen T Brown; George I Getrajdman; Joseph P Erinjeri; Anne Covey; Hooman Yarmohammadi; Etay Ziv; Constantinos T Sofocleous; Franz Edward Boas
Journal:  Acad Radiol       Date:  2018-03-27       Impact factor: 3.173

6.  Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE.

Authors:  Jan B Hinrichs; Hoen-Oh Shin; Daniel Kaercher; Davut Hasdemir; Tim Murray; Till Kaireit; Carolin Lutat; Arndt Vogel; Bernhard C Meyer; Frank K Wacker; Thomas Rodt
Journal:  Eur Radiol       Date:  2016-01-14       Impact factor: 5.315

7.  Heterogeneity analysis of triphasic CT scan perfusion parameters in differential diagnosis of hepatocellular carcinoma and hemangioma.

Authors:  Guodong Pang; Zuyun Duan; Chunchun Shao; Fang Zhao; Hai Zhong; Guangrui Shao
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

8.  Comparative analysis of tumor-associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study.

Authors:  Ligang Chen; Yifei Zheng; Hongjian Zhang; Heng Pan; Qiusong Liu; Xu Zhou; Wei Wei; Yun Liu; Maochuan Zhen; Jinling Wang; Jianyin Zhou; Yilin Zhao
Journal:  Oncol Lett       Date:  2018-07-02       Impact factor: 2.967

9.  Tumor attenuation and quantitative analysis of perfusion parameters derived from tri-phasic CT scans in hepatocellular carcinoma: Relationship with histological grade.

Authors:  Guodong Pang; Chunchun Shao; Yao Lv; Fang Zhao
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

10.  A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver.

Authors:  Pei Nie; Guangjie Yang; Jian Guo; Jingjing Chen; Xiaoli Li; Qinglian Ji; Jie Wu; Jingjing Cui; Wenjian Xu
Journal:  Cancer Imaging       Date:  2020-02-24       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.